Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?

Autor: Crocco M; Neuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy., Verrico A; Neuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Milanaccio C; Neuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Piccolo G; Neuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy., De Marco P; UOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Gaggero G; Department of Clinical Pathology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy., Iurilli V; Pharmacy Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Di Profio S; Clinical Psychology, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Malerba F; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy., Panciroli M; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy., Giordano P; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy., Calevo MG; Epidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Casalini E; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy.; Department of Pediatrics, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Di Iorgi N; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy.; Department of Pediatrics, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy., Garrè ML; Neuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
Jazyk: angličtina
Zdroj: Cancers [Cancers (Basel)] 2022 May 29; Vol. 14 (11). Date of Electronic Publication: 2022 May 29.
DOI: 10.3390/cancers14112693
Abstrakt: BRAF inhibitors, in recent years, have played a central role in the disease control of unresectable BRAF-mutated pediatric low-grade gliomas (LGGs). The aim of the study was to investigate the acute and long-term effects of vemurafenib on the lipid metabolism in children treated for an LGG. In our cohort, children treated with vemurafenib ( n = 6) exhibited alterations in lipid metabolism a few weeks after starting, as was demonstrated after 1 month ( n = 4) by the high plasma levels of the total cholesterol (TC = 221.5 ± 42.1 mg/dL), triglycerides (TG = 107.8 ± 44.4 mg/dL), and low-density lipoprotein (LDL = 139.5 ± 51.5 mg/dL). Despite dietary recommendations, the dyslipidemia persisted over time. The mean lipid levels of the TC (222.3 ± 34.7 mg/dL), TG (134.8 ± 83.6 mg/dL), and LDL (139.8 ± 46.9 mg/dL) were confirmed abnormal at the last follow-up (45 ± 27 months, n = 6). Vemurafenib could be associated with an increased risk of dyslipidemia. An accurate screening strategy in new clinical trials, and a multidisciplinary team, are required for the optimal management of unexpected adverse events, including dyslipidemia.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje